Research Peptide Catalog

Paired GHRH-receptor analogue and selective GHS-R agonist studied for complementary dual-receptor mechanisms and additive GH pulse data in preclinical models.

Proprietary research peptide blend investigated for fibrillar protein synthesis pathway modulation, ROS scavenging assays, and dermal fibroblast receptor interaction in vitro.

Proprietary research peptide blend studied for metabolic regulation, cellular energy pathways, and stress-response modulation in controlled laboratory environments.

BPC-157 (5mg) + TB-500 (5mg) paired for complementary repair-pathway research in preclinical and in vitro laboratory models.

Selective GHS-R (ghrelin receptor) agonist pentapeptide studied for pulsatile GH secretion with minimal cortisol or prolactin interference.

Synthetic GHRH analogue with a trans-3-hexenoic acid modification for extended half-life. Studied for GH axis modulation and visceral adipose tissue research.

Full 191-amino acid chain recombinant somatotropin identical in sequence to endogenous pituitary-derived GH. Studied for GH receptor binding kinetics, IGF-1 axis signaling, and downstream anabolic pathway activation in cell-based models.

Long-acting IGF-1 analogue with Arg3 substitution and N-terminal extension that reduces IGFBP affinity. Studied for IGF-1 receptor binding kinetics and PI3K/Akt and MAPK/ERK pathway activation.

Mitochondria-derived peptide encoded within the 12S rRNA gene. Studied for AMPK pathway activation, metabolic regulation, and mitochondrial biogenesis signaling.

Mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane. Studied for cardiolipin interaction and electron transport chain efficiency.

Naturally occurring copper-binding tripeptide found in human plasma. Studied for extracellular matrix remodeling, copper ion chelation, and gene expression modulation.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for telomerase activation, telomere elongation, and circadian rhythm regulation in laboratory models.

Triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied for multi-receptor metabolic signaling and energy homeostasis.

Dual GLP-1/GIP receptor co-agonist studied for incretin pathway synergy, insulin secretion modulation, and body weight regulation in preclinical metabolic models.

Synthetic heptapeptide analogue of tuftsin studied for anxiolytic-like effects, BDNF modulation, and GABAergic pathway interaction in preclinical models.

Synthetic ACTH(4-7) analogue with Pro-Gly-Pro extension studied for BDNF upregulation, dopaminergic and serotonergic pathway modulation, and neuroprotective signaling.

Angiotensin IV analogue studied for HGF/c-Met signaling pathway activation and synaptogenic mechanisms in preclinical cognitive research models.

Essential coenzyme in cellular redox reactions and NAD+/NADH cycling. Studied for sirtuin activation, PARP pathway modulation, and mitochondrial bioenergetics.

Cyclic heptapeptide melanocortin receptor agonist derived from alpha-MSH. Studied for MC3R/MC4R binding affinity, hypothalamic signaling, and dopaminergic pathway interaction in preclinical models.

Adamantane-modified Semax analogue with enhanced lipophilicity and CNS penetration. Studied for BDNF upregulation, dopaminergic modulation, and neuroprotective signaling in preclinical cognitive models.

Tripeptide Glu-Asp-Arg studied for pineal gland regulation, circadian rhythm signaling, and neuroprotective mechanisms in preclinical models.